A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer
The present study aimed to evaluate the anti-tumor efficacy of the epidermal growth factor receptor (EGFR)-targeting recombinant fusion protein Fv-LDP-D3 and its antibody-drug conjugate Fv-LDP-D3-AE against esophageal cancer. Fv-LDP-D3, consisting of the fragment variable (Fv) of an anti-EGFR antibo...
Saved in:
Main Authors: | Shiming He (Author), Chunyan Zhao (Author), Hongyu Tao (Author), Weijin Sheng (Author), Ruijuan Gao (Author), Xiujun Liu (Author), Yongsu Zhen (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
"Stapling" scFv for multispecific biotherapeutics of superior properties
by: Lauren E. Boucher, et al.
Published: (2023) -
Chaperone-Assisted Soluble Expression of a Humanized Anti-EGFR ScFv Antibody in E. Coli
by: Kamal Veisi, et al.
Published: (2015) -
Production of a germline-humanized cetuximab scFv and evaluation of its activity in recognizing EGFR- overexpressing cancer cells
by: Arsham Banisadr, et al.
Published: (2018) -
The improvement of anti-HER2 scFv soluble expression in Escherichia coli
by: Farzaneh Farshdari, et al.
Published: (2020) -
Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
by: Kristina M.J. Aertker, et al.
Published: (2024)